PRN: Underground Mining Giant - Digging Deep for Value
Mining services leader trading at 3.1x EV/EBITDA vs 9.0x peer median, fair value $3.92 vs current $2.02, strong execution track record
View noteMining services leader trading at 3.1x EV/EBITDA vs 9.0x peer median, fair value $3.92 vs current $2.02, strong execution track record
View noteFair value $3.62 vs current $1.94 (87% upside). Market-leading non-bank lender with 48.8% EBITDA margins, 12.1% ROIC, transforming to capital-light servicing model.
View noteTrading at $0.65 vs $11.26 fair value (1,632% upside). PALM scheme monopoly, Queensland infrastructure catalyst, margins recovering 3.0% to 9.6%. High risk, exceptional reward potential.
View noteMedical device manufacturer with 54% revenue growth but trading at 237x EBITDA. Fair value A$1.06 vs current A$1.48 implies 28% downside risk.
View noteAustralia's largest independent game developer attempting high-risk transformation. Fair value $0.089 vs current $0.21. Quality score 3.7/10, 65% IP failure probability.
View notePilbara Minerals analysis: Current $2.20 vs fair value $0.85, SELL rating, extreme overvaluation despite operational excellence and tier-one assets.
View noteIncome LIC trading at unsustainable 22.3% premium to NTA. Fair value $1.30 vs current $1.41. Systematic advantages eroding, competitive pressure mounting.
View notePropel Funeral Partners trades at $5.04 vs $3.83 fair value with 32% overvaluation despite solid fundamentals and demographic tailwinds creating asymmetric downside risk.
View noteTrading at 5.1x EBITDA vs peer median 12.5x, fair value $0.645 vs current $0.26 implies 148% upside through demographic tailwinds and platform integration.
View noteHOLD rating with $10.78 fair value vs $11.20 current price. Market leader with 25.8% share, 5.1% dividend yield, facing battery execution risks.
View noteOrora trades at A$1.89 versus A$2.38 fair value with 26% upside potential. Strong market positions offset by customer concentration risks and integration challenges.
View noteHealthcare IT company trading at $0.24 vs $0.095 fair value. Strong recurring revenue model offset by execution risks and EMR competition. 60% overvalued.
View note